Toragen, Inc. provides update on data from its ongoing Phase 1 Clinical Trial of TGN-S11 in patients with Stage 4 HPV-associated cancers.

SAN DIEGO, April 15, 2025--Today, Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses ...

Tweet this “The acceptance of the TGN-S11 IND is an important milestone for Toragen, as we work toward a treatment for HPV-induced cancers,” said Sandra Coufal, MD, Toragen’s CEO.